Adequacy of the national quality forum's colon cancer adjuvant chemotherapy quality metric: Is 4 months soon enough?

Annals of Surgery

Volumn 262, Issue 2, 2015, Pages 312-320

  Massarweh, Nader N ^a   Haynes, Alex B ^b   Chiang, Yi Ju ^a   Chang, George J ^a   You, Y Nancy ^a   Feig, Barry W ^a   Cormier, Janice N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

adjuvant chemotherapy; colon cancer; National Quality Forum; quality metric; quality of care

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; THERAPY DELAY; CANCER STAGING; CLINICAL PROTOCOL; COHORT ANALYSIS; COLON RESECTION; COLONIC NEOPLASMS; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT;

AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL PROTOCOLS; COHORT STUDIES; COLECTOMY; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; QUALITY INDICATORS, HEALTH CARE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84938252164     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000859     Document Type: Article

References (36)

1. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 1999; 17: 1356-1363
2. Andre T, Boni C, Navarro M, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27: 3109-3116
3. Laurie JA, Moertel CG, Fleming TR, Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989; 7: 1447-1456
4. Moertel CG, Fleming TR, Macdonald JS, Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322: 352-358
5. Wolmark N, Rockette H, Mamounas E, Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999; 17: 3553-3559
6. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Colon Cancer. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed June 29, 2013
7. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 1444-1450
8. Laubert T, Habermann JK, Hemmelmann C, Metachronous metastasis-And survival-Analysis show prognostic importance of lymphadenectomy for colon carcinomas. BMC Gastroenterol. 2012; 12: 24
9. Biagi JJ, Raphael MJ, Mackillop WJ, Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-Analysis. JAMA. 2011; 305: 2335-2342
10. National Quality Forum. National Voluntary Consensus Standards for Quality of Cancer Care. Available at: http://www.qualityforum.org/Publications/2009/05/National-Voluntary-Consensus-Standards-for-Quality-of-Cancer-Care.aspx. Accessed July 3, 2013
11. Malin JL, Schneider EC, Epstein AM, Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol. 2006; 24: 626-634
12. Chau I, Norman AR, Cunningham D, A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005; 16: 549-557
13. Hershman D, Hall MJ, Wang X, Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006; 107: 2581-2588
14. Des Guetz G, Nicolas P, Perret GY, Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-Analysis. Eur J Cancer. 2010; 46: 1049-1055
15. Bilimoria KY, Stewart AK, Winchester DP, The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008; 15: 683-690
16. Steele GD Jr, Winchester DP, Menck HR,. The National Cancer Data Base A mechanism for assessment of patient care. Cancer. 1994; 73: 499-504
17. Winchester DP, Stewart AK, Phillips JL, The National Cancer Data Base: past, present, and future. Ann Surg Oncol. 2010; 17: 4-7
18. Wilkinson NW, Yothers G, Lopa S, Long-Term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05 A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010; 17: 959-966
19. National Quality Forum. NQF Endorses Additional Cancer Measures. Available at: http://www.qualityforum.org/News-And-Resources/Press-Releases/2012/NQF-Endorses-Additional-Cancer-Measures.aspx. Accessed January 28, 2014
20. National Quality Forum. Endorsement Summaries. Available at: http://www.qualityforum.org/News-And-Resources/Endorsement-Summaries/Endorsement-Summaries.aspx. Accessed January 28, 2014
21. Merkow RP, Bentrem DJ, Mulcahy MF, Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg. 2013; 258: 847-853
22. Shea AM, Curtis LH, Hammill BG, Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. JAMA. 2008; 300: 189-196
23. Zhang J, Yu KF,. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998; 280: 1690-1691
24. Hu CY, Xing Y, Cormier JN, Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer. 2013; 119: 1900-1907
25. Ambler G, Omar RZ, Royston P, A comparison of imputation techniques for handling missing predictor values in a risk model with a binary outcome. Stat Methods Med Res. 2007; 16: 277-298
26. Giorgi R, Belot A, Gaudart J, The performance of multiple imputation for missing covariate data within the context of regression relative survival analysis. Stat Med. 2008; 27: 6310-6331
27. National Quality Forum. Membership in NQF. Available at: http://www.qualityforum.org/Membership/Membership-in-NQF.aspx. Accessed November 23, 2013
28. National Quality Forum. 2012 NQF Report to Congress. Available at: http://www.qualityforum.org/Publications/2012/03/2012-NQF-Report-to-Congress.aspx. Accessed November 23, 2013
29. Panzer RJ, Gitomer RS, Greene WH, Increasing demands for quality measurement. JAMA. 2013; 310: 1971-1980
30. Cohen ME, Bilimoria KY, Ko CY, Variability in length of stay after colorectal surgery: assessment of 182 hospitals in the national surgical quality improvement program. Ann Surg. 2009; 250: 901-907
31. Hendren S, Birkmeyer JD, Yin H, Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. Dis Colon Rectum. 2010; 53: 1587-1593
32. van der Geest LG, Portielje JE, Wouters MW, Complicated postoperative recovery increases omission, delay and discontinuation of adjuvant chemotherapy in patients with colon cancer stage III. Colorectal Dis. 2013; 15: e582-e591
33. Wright JD, Neugut AI, Wilde ET, Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol. 2011; 29: 3408-3418
34. El Shayeb M, Scarfe A, Yasui Y, Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review. BMC Res Notes. 2012; 5: 269
35. Bilimoria KY, Bentrem DJ, Stewart AK, Comparison of Commission on Cancer-Approved and-nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009; 27: 4177-4181
36. Lerro CC, Robbins AS, Phillips JL, Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol. 2013; 20: 1759-1765